Aclaris Therapeutics, Inc.·4

Oct 5, 4:37 PM ET

Tullman Stephen A. 4

4 · Aclaris Therapeutics, Inc. · Filed Oct 5, 2018

Insider Transaction Report

Form 4
Period: 2018-10-04
Transactions
  • Purchase

    Common Stock

    2018-10-04$14.00/sh+7,100$99,370177,457 total
Holdings
  • Common Stock

    (indirect: By Trust)
    394,014
Footnotes (3)
  • [F1]The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on March 23, 2018.
  • [F2]This transaction was executed in multiple trades at prices ranging from $13.90 to $14.00, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
  • [F3]These shares are held by the 2007 Irrevocable Trust of Stephen A. Tullman, for which the reporting person's spouse serves as the trustee.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION